However, because of the ubiquitous expression of CD47 and its high expression on newly formed red blood cells (RBC)10, targeting CD47 should be carefully designed to prevent both poor pharmacokinetics, due to target mediated drug disposition, and on-target off-tumor depletion of RBCs. The gene discussed is CD47; the disease is neoplasm.